Skip to main content

ABBOTT LABORATORIES

corporate_fare Company Profile

ABBOTT LABORATORIES

ABT·NYSE·Life Sciences·CIK 0000001800

Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business involves the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market. This acquisition is subject to customary closing conditions, including shareholder approval and regulatory clearances. Abbott operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment includes a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers or public warehouses. Some products are co-marketed, co-promoted, or licensed from other companies. Key products in this segment's therapeutic portfolios include: - Gastroenterology products: Creon™ for pancreatic exocrine insufficiency; Duspatal™ and Dicetel™ for irritable bowel syndrome or biliary spasm; Heptral™, Transmetil™, and Samyr™ for intrahepatic cholestasis or depressive symptoms; and Duphalac™ for colon rhythm regulation. - Women's health products: Duphaston™ for gynecological disorders; and Femoston™ for postmenopausal hormone replacement therapy. - Cardiovascular and metabolic products: Lipanthyl™ and TriCor™ for dyslipidemia and diabetic retinopathy; Omacor™ for hypertriglyceridemia; Physiotens™ for hypertension; and Synthroid™ for hypothyroidism. - Pain and central nervous system products: Serc™ for Ménière's disease and vestibular vertigo; Brufen™ for pain, fever, and inflammation; and Sevedol™ for severe migraines. - Respiratory drugs and vaccines: including the anti-infective clarithromycin.

ABBOTT LABORATORIES (NYSE:ABT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for ABT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Abbott Completes $21 Billion Exact Sciences Acquisition, Bolstering Cancer Diagnostics
  • Abbott Completes $21 Billion Acquisition of Exact Sciences, Becomes Leader in Cancer Diagnostics
  • Abbott Seeks Shareholder Approval for New Equity Plans Authorizing 9.0% Potential Dilution
  • Abbott Laboratories Completes $20 Billion Senior Notes Offering for Exact Sciences Acquisition
  • Abbott Faces New Trial Over Infant Formula Causing Deadly Disease; Prior Verdicts Reached $495M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.33B
Net Income
$6.52B
Diluted EPS
$3.72
Op. Cash Flow
$9.57B
Free Cash Flow
$7.39B
Gross Profit
$25.01B
Operating Income
$8.05B
Cash & Equivalents
$8.52B
Total Debt
$12.93B
Debt / Equity
0.25×
Net Margin
14.7%
Shares Outstanding
1.74B sh
Source: 10-K · filed 2026-02-20 · accession 0001628280-26-010185
$97.51 +0.01% today
52-week range · as of 2026-08-20 $81.97 – $137.49
Market cap
$168.71B
Volume
8.7M (1.0× avg)
3-mo avg 8.5M
Live data · 2026-10-05 03:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABT - Filings & News (Page 2)

ABT
Mar 23, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $107.14
Real-time Price: $97.51 info
Change: -$9.63 (-9%) info
Market Cap: $168.712B info
ABT
Mar 23, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $106.67
Real-time Price: $97.51 info
Change: -$9.16 (-9%) info
Market Cap: $168.712B info
ABT
Mar 13, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $108.02
Real-time Price: $97.51 info
Change: -$10.51 (-10%) info
Market Cap: $168.712B info
ABT
Mar 09, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $112.65
Real-time Price: $97.51 info
Change: -$15.14 (-13%) info
Market Cap: $168.712B info
ABT
Mar 04, 2026, 6:00 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $113.68
Real-time Price: $97.51 info
Change: -$16.17 (-14%) info
Market Cap: $168.712B info
ABT
Feb 25, 2026, 7:01 AM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $114.26
Real-time Price: $97.51 info
Change: -$16.75 (-15%) info
Market Cap: $168.712B info
ABT
Feb 23, 2026, 6:18 PM EST
Filing Type: FWP
Importance Score:
9
Price at Filing: $111.97
Real-time Price: $97.51 info
Change: -$14.46 (-13%) info
Market Cap: $168.712B info
ABT
Feb 20, 2026, 4:05 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $112.21
Real-time Price: $97.51 info
Change: -$14.70 (-13%) info
Market Cap: $168.712B info
ABT
Jan 22, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $113.60
Real-time Price: $97.51 info
Change: -$16.09 (-14%) info
Market Cap: $168.712B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets